Neurosense Therapeutics Ltd. (NRSN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NeuroSense Therapeutics has announced promising results from its PARADIGM study, showing that its drug PrimeC significantly slows disease progression and boosts survival rates in ALS patients. The study suggests a 33% improvement in disease progression and a 58% increase in survival rates for those starting treatment with PrimeC, potentially redefining ALS care standards.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
